RPL17 and neoplasm: The expression of PD-L1 in tumour cells activates the PD-1/PD-L1pathway by binding to the PD-1 receptor on activated T-lymphocytes which leads to inhibition of cytotoxic T cells against cancer, and thus permitting cancer progression and metastasis.